Consider 505(b)(2) Pathway [Design Issues]

posted by bebac_fan – US, 2018-05-05 19:08 (2154 d 21:52 ago) – Posting: # 18756
Views: 2,799

I think this would need to go through a NDA/505(b)(2) pathway rather than an ANDA.

In this case, comparative efficacy, rather than BE, will be considered pivotal.

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
108 visitors (0 registered, 108 guests [including 11 identified bots]).
Forum time: 16:01 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5